Sarthy JF - Search Results

1

KMT2A oncoproteins induce epigenetic resistance to targeted therapies.

Janssens DH, Duran M, Otto DJ, Wu W, Xu Y, Kirkey D, Mullighan CG, Yi JS, Meshinchi S, Sarthy JF, Ahmad K, Henikoff S. Janssens DH, et al. Among authors: sarthy jf. bioRxiv [Preprint]. 2024 Aug 12:2023.12.29.573681. doi: 10.1101/2023.12.29.573681. bioRxiv. 2024. PMID: 38234854 Free PMC article. Preprint.

2

A light scattering assay for arachidonic acid-induced tau fibrillization without interfering micellization.

Sarthy J, Gamblin TC. Sarthy J, et al. Anal Biochem. 2006 Jun 1;353(1):150-2. doi: 10.1016/j.ab.2006.03.011. Epub 2006 Mar 29. Anal Biochem. 2006. PMID: 16620751 No abstract available.

3

Response to Pembrolizumab in a Patient With Xeroderma Pigmentosum and Advanced Squamous Cell Carcinoma.

Steineck A, Krumm N, Sarthy JF, Pritchard CC, Chapman T, Stacey AW, Vitanza NA, Cole B. Steineck A, et al. Among authors: sarthy jf. JCO Precis Oncol. 2019 Sep 20;3:PO.19.00028. doi: 10.1200/PO.19.00028. eCollection 2019. JCO Precis Oncol. 2019. PMID: 32923855 Free PMC article. No abstract available.

4

Endolymphatic exclusion for the treatment of pediatric chylous ascites secondary to neuroblastoma resection: report of two cases.

Woerner A, Shin DS, Chick JFB, Smith CA, Sarthy JF, Monroe EJ. Woerner A, et al. Among authors: sarthy jf. Radiol Case Rep. 2020 May 19;15(7):1044-1049. doi: 10.1016/j.radcr.2020.04.060. eCollection 2020 Jul. Radiol Case Rep. 2020. PMID: 32461775 Free PMC article.

5

Pediatric 8p11 eosinophilic myeloproliferative syndrome (EMS): A case report and review of the literature.

Sarthy JF, Reddivalla N, Radhi M, Chastain K. Sarthy JF, et al. Pediatr Blood Cancer. 2017 May;64(5). doi: 10.1002/pbc.26310. Epub 2016 Nov 3. Pediatr Blood Cancer. 2017. PMID: 27808462 Review.

6

Molecularly Targeted Treatments for NF1-Mutant Diffuse Intrinsic Pontine Glioma.

Vitanza NA, Khalatbari H, Ermoian R, Sarthy J, Lockwood CM, Cole BL, Leary SES. Vitanza NA, et al. J Appl Lab Med. 2021 Mar 1;6(2):550-553. doi: 10.1093/jalm/jfaa086. J Appl Lab Med. 2021. PMID: 32862234 No abstract available.

7

Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.

Vitanza NA, Biery MC, Myers C, Ferguson E, Zheng Y, Girard EJ, Przystal JM, Park G, Noll A, Pakiam F, Winter CA, Morris SM, Sarthy J, Cole BL, Leary SES, Crane C, Lieberman NAP, Mueller S, Nazarian J, Gottardo R, Brusniak MY, Mhyre AJ, Olson JM. Vitanza NA, et al. Neuro Oncol. 2021 Mar 25;23(3):376-386. doi: 10.1093/neuonc/noaa249. Neuro Oncol. 2021. PMID: 33130903 Free PMC article.

8

dCas9 fusion to computer-designed PRC2 inhibitor reveals functional TATA box in distal promoter region.

Levy S, Somasundaram L, Raj IX, Ic-Mex D, Phal A, Schmidt S, Ng WI, Mar D, Decarreau J, Moss N, Alghadeer A, Honkanen H, Sarthy J, Vitanza A, Hawkins RD, Mathieu J, Wang Y, Baker D, Bomsztyk K, Ruohola-Baker H. Levy S, et al. Cell Rep. 2022 Mar 1;38(9):110457. doi: 10.1016/j.celrep.2022.110457. Cell Rep. 2022. PMID: 35235780 Free PMC article.

9

Acute enlargement of a vascular plaque and gait changes in a young girl.

Tedesco KT, Sarthy J, Pinto N, Boos MD. Tedesco KT, et al. BMJ. 2018 Nov 28;363:k4679. doi: 10.1136/bmj.k4679. BMJ. 2018. PMID: 30487229 No abstract available.

10

Human RAP1 inhibits non-homologous end joining at telomeres.

Sarthy J, Bae NS, Scrafford J, Baumann P. Sarthy J, et al. EMBO J. 2009 Nov 4;28(21):3390-9. doi: 10.1038/emboj.2009.275. Epub 2009 Sep 17. EMBO J. 2009. PMID: 19763083 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30 results

Search Page

Filters